A61K 39/395
Antibodies
Official title: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K39/395 (Antibodies) appears on 12,866 US grants and 25,525 published applications in this corpus.
Search patents in A61K- Granted patents
- 12,866
- Published applications
- 25,525
- Assignees
- 5,480
- Inventors
- 33,309
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 4 | 0 |
| 1977 | 7 | 0 |
| 1978 | 7 | 0 |
| 1979 | 5 | 0 |
| 1980 | 7 | 0 |
| 1981 | 10 | 0 |
| 1982 | 5 | 0 |
| 1983 | 12 | 0 |
| 1984 | 9 | 0 |
| 1985 | 8 | 0 |
| 1986 | 5 | 0 |
| 1987 | 15 | 0 |
| 1988 | 11 | 0 |
| 1989 | 13 | 0 |
| 1990 | 21 | 0 |
| 1991 | 8 | 0 |
| 1992 | 19 | 0 |
| 1993 | 17 | 0 |
| 1994 | 12 | 0 |
| 1995 | 14 | 0 |
| 1996 | 14 | 0 |
| 1997 | 32 | 0 |
| 1998 | 58 | 0 |
| 1999 | 37 | 0 |
| 2000 | 37 | 0 |
| 2001 | 52 | 33 |
| 2002 | 51 | 132 |
| 2003 | 34 | 625 |
| 2004 | 44 | 227 |
| 2005 | 35 | 261 |
| 2006 | 84 | 283 |
| 2007 | 148 | 289 |
| 2008 | 148 | 337 |
| 2009 | 148 | 463 |
| 2010 | 186 | 568 |
| 2011 | 217 | 698 |
| 2012 | 290 | 707 |
| 2013 | 453 | 1173 |
| 2014 | 593 | 1349 |
| 2015 | 718 | 1245 |
| 2016 | 781 | 1416 |
| 2017 | 852 | 1508 |
| 2018 | 762 | 1645 |
| 2019 | 935 | 1710 |
| 2020 | 1012 | 1755 |
| 2021 | 1012 | 1886 |
| 2022 | 907 | 1794 |
| 2023 | 813 | 1616 |
| 2024 | 851 | 1569 |
| 2025 | 843 | 1277 |
| 2026 | 510 | 959 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- A61K 39/39533Against materials from animals9,291
- A61K 39/39591Stabilisation, fragmentation988
- A61K 39/42Viral458
- A61K 39/40Bacterial313
- A61K 39/44Antibodies bound to carriers241
- A61K 39/39516From serum, plasma96
- A61K 39/39583Against materials not provided for elsewhere71
- A61K 39/39575Against materials from other living beings excluding bacteria and viruses55
All 9 subgroupsShow fewer
Recent patents
- Anti-Claudin18.2 antigen-binding fragment or antibody, and use thereof182551196 Oct 2026US 12,751,972 B2Guangzhou Bio-Gene Technology Co., Ltd
- Enhancement of immune response with oral immunoglobulin polypeptides6 Oct 2026US 12,752,004 B2Iogenetics, LLC
- Compositions and methods of treating lupus nephritis6 Oct 2026US 12,752,005 B2Genentech, Inc.
- Antibodies binding to alpha-synuclein for therapy and diagnosis6 Oct 2026US 12,753,223 B2AC Immune SA
- TGFbeta1-binding immunoglobulins and use thereof6 Oct 2026US 12,753,226 B2Scholar Rock, Inc.
- Compositions and methods for treating cancer by targeting bach18 Oct 2026US 2026/0306455 A1
- Composition for removing and inhibiting senescent cells, and uses thereof8 Oct 2026US 2026/0306460 A1Lifeceutix Co., Ltd.
- Pharmaceutical combination for cancer treatment8 Oct 2026US 2026/0306466 A1Miyarisan Pharmaceutical Co., Ltd.
- Inhaled statins as bronchodilators to improve lung function in respiratory diseases8 Oct 2026US 2026/0306477 A1Beth Israel Deaconess Medical Center, Inc.
- Inverse agonists of rar related orphan receptors (rors)8 Oct 2026US 2026/0306484 A111949098 CANADA INC. (NUREDCO) c/o Jean I. TCHERVENKOV
Most cited
By later US patents
- Interleukin-1α antibodies1,029US 8,034,337 B2Xbiotech, Inc. · 2011
- Antigen-adjuvant compositions and methods1,024US 8,790,658 B2Sanofi Pasteur Limited · 2014
- Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics940US 8,008,449 B2Medarex, Inc. · 2011
- Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation733US 9,101,621 B2Celgene Corporation · 2015
- Encapsulation of biological material667US 4,352,883 ADamon Corporation · 1982